FDA's April 2026 proposal to remove semaglutide and tirzepatide from the 503B bulks list - with a public comment period through June 2026 - creates a genuine decision window: buyers who enroll now are committing to a subscription before the outcome of that proposal is known
Stop one before starting the other
Both work for weight loss
Why GLP-1 Medications Are So Expensive Patent Protection and Market Demand Brand-name GLP-1 medications are still under patent
Using advanced tracer methodologies, the researchers identified a fascinating metabolic phenomenon they termed "brain glucose steal." Due to systemic mitochondrial impairment, non-brain organs were essentially stealing glucose intended for the central nervous system, starving the brain of energy and driving cognitive dysfunction
Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial